Enzo Biochem, Inc. (ENZ) appointed Mary Tagliaferri, MDappointed to the company’s Board of Directors effective immediately.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The CEO and chairman of Enzo Biochem, Elazar Rabbani said that 2020 was a good year for the company with massive progress in advancing our business plan to achieveprofitability and we have set new goals for 2021.
He further said that Dr Tagliaferri is a highly experienced industry leader with global experience in business development, clinical research and development, world-wide regulatory matters and medical affairs. The CEO hopes that she will play a leading role in the company’s continued success and future growth at Enzo.
Dr Tagliaferri is currently working as a Senior Vice President and Executive Clinical Fellow. In past, she has worked as a Chief Medical Officer at Nektar Therapeutics. She has a Bachelor of Science degree at Cornell University and a medical degree at the University of CaliforniaSan Francisco. Dr Tagliaferri was Most Influential Women in Business lists by the San Francisco Business Times in 2019 and she was Woman of the Year in 2019.
On her appointment, she expressed her pleasure and said that it is time to presents so many important opportunities for the company to continue to show innovation and leadership in response to the COVID-19 pandemic and other emerging health challenges. She said that she is looking forward to work with other board members to maximize the full range of business opportunities in the coming years.
The DrRabbanisaid that recently, Enzo has advanced well in business strategy, including FDA Emergency Use Authorization for our GenFlex™ platform for COVID-19 testing. The company also recently introduce microplate reader for use with our ELISA and assay kits. He further said that Dr Tagliaferri’s experience will be vital for the company to continue this momentum.
